Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-35.3
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales258¥ millionYear on year -35.3%Progress 16.0%
Operating profit-93¥ million
Ordinary income-89¥ million
Net income attributable to owners of the parent-91¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share-¥22.38
Financial position at period-end
Total assets2,068¥ million
of which net assets 1,464 ¥ millionEquity ratio 70.1%vs. prior year-end -0.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Regional salesRegion Domestic / Field Pharmacological efficacy studies / Current-period value ¥2,382 thousand / Prior-year period value ¥890 thousand, Region Overseas expansion / Field Pharmacological efficacy studies / Current-period value ¥782 thousand / Prior-year period value ¥30,291 thousand, Region Domestic / Field Safety and related studies / Current-period value ¥115,585 thousand / Prior-year period value ¥71,213 thousand, Region Overseas expansion / Field Safety and related studies / Current-period value ¥140,205 thousand / Prior-year period value ¥297,857 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥1,610 million (YoY +2.9%)
Operating profit¥85 million (YoY +3.7%)
Ordinary income¥87 million (YoY -33.5%)
Net income¥76 million (YoY -38.6%)
Annual Dividend Forecast¥0 → ¥0
Factors Behind Changes in Business Performance
Orders for hepatitis-related contract testing in overseas markets were delayed. No shipments to major overseas customers had been scheduled for the first quarter, and certain contract testing projects were also delayed. Some costs, including cost of sales, business travel expenses and transportation expenses, decreased, but this was insufficient to offset the decline in revenue.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Material subsequent eventsThe Board of Directors resolved to dissolve and liquidate the consolidated subsidiary CMHL Consortium LLC. The dissolution date and liquidation completion date have not been determined. The Company expects to transfer the foreign currency translation adjustment and incur liquidation-related expenses, but the impact on consolidated results is expected to be immaterial.
Breakdown of extraordinary income (loss)Extraordinary income Not disclosed / Extraordinary loss No entry for the current period (loss on disposal of non-current assets: "-")
Depreciation and amortization¥8,431 thousand
Orders received and order backlogOrders received ¥247,165 thousand / Order backlog ¥560,996 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End4,076,933 Shares
Treasury Shares at Period-End6,737 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥258 million (YoY -35.3%) |
| Operating profit | ¥-93 million |
| Ordinary income | ¥-89 million |
| Profit attributable to owners of the parent | ¥-91 million |
| Net income per share | -¥22.38 |
| Equity ratio | End of the current fiscal period 70.1 / End of previous period 70.2 |
| Total assets | ¥2,068 million |
| Net assets | ¥1,464 million |
| Full-year earnings forecast | Net Sales ¥1,610 million (YoY +2.9%) / Operating profit ¥85 million (YoY +3.7%) / Ordinary income ¥87 million (YoY -33.5%) / Net income ¥76 million (YoY -38.6%) |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Regional sales | Region Domestic / Field Pharmacological efficacy studies / Current-period value ¥2,382 thousand / Prior-year period value ¥890 thousand, Region Overseas expansion / Field Pharmacological efficacy studies / Current-period value ¥782 thousand / Prior-year period value ¥30,291 thousand, Region Domestic / Field Safety and related studies / Current-period value ¥115,585 thousand / Prior-year period value ¥71,213 thousand, Region Overseas expansion / Field Safety and related studies / Current-period value ¥140,205 thousand / Prior-year period value ¥297,857 thousand |
| Orders received and order backlog | Orders received ¥247,165 thousand / Order backlog ¥560,996 thousand |
| Depreciation and amortization | ¥8,431 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss No entry for the current period (loss on disposal of non-current assets: "-") |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | The Board of Directors resolved to dissolve and liquidate the consolidated subsidiary CMHL Consortium LLC. The dissolution date and liquidation completion date have not been determined. The Company expects to transfer the foreign currency translation adjustment and incur liquidation-related expenses, but the impact on consolidated results is expected to be immaterial. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 4,076,933 Shares |
| Treasury Shares at Period-End | 6,737 Shares |
| Factors Behind Changes in Business Performance | Orders for hepatitis-related contract testing in overseas markets were delayed. No shipments to major overseas customers had been scheduled for the first quarter, and certain contract testing projects were also delayed. Some costs, including cost of sales, business travel expenses and transportation expenses, decreased, but this was insufficient to offset the decline in revenue. |
Items this document does not state (11)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitImpairment loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Orders for hepatitis-related contract testing in overseas markets were delayed, and no shipments to major customers had been scheduled for the first quarter. Revenue therefore declined due to these factors and delays in certain contract testing projects. Some costs, including cost of sales, business travel expenses and transportation expenses, decreased, but this was insufficient to offset the decline in revenue.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.